Literature DB >> 6149470

Classification of drugs according to receptor binding profiles.

A Closse, W Frick, A Dravid, G Bolliger, D Hauser, A Sauter, H J Tobler.   

Abstract

The affinity for eight different neurotransmitter receptors of about forty drugs, used for the treatment of various central nervous system disorders, was determined following in vitro receptor binding assays. Our findings indicate that, in spite of widely varying chemical structures and often poorly understood mechanisms of action, the similarities in the "affinity profiles" permit a clinically meaningful classification of these drugs. Such an approach would thus be useful in the assessment of newly synthesized compounds at an early stage of drug development.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149470     DOI: 10.1007/bf00500901

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  32 in total

1.  Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease.

Authors:  G J Wastek; H I Yamamura
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

2.  Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

3.  (3,4-Dihydroxy-phenylamino)-2-imidazoline (DPI), a new potent agonist at dopamine receptors mediating neuronal inhibition.

Authors:  H Struyker Boudier; L Teppema; A Cools; J Van Rossum
Journal:  J Pharm Pharmacol       Date:  1975-11       Impact factor: 3.765

4.  Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide.

Authors:  J P Green; C L Johnson; H Weinstein; S Maayani
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  The action of microelectrophoretically applied (3,4-dihydroxy-phenylamino)-2-imidazoline (DPI) on single cortical neurones.

Authors:  P Bevan; C M Bradshaw; R Y Pun; N T Slater; E Szabadi
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

6.  Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.

Authors:  M G Caron; M Beaulieu; V Raymond; B Gagné; J Drouin; R J Lefkowitz; F Labrie
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

Review 7.  Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.

Authors:  A Closse; G Bolliger; A Dravid; W Frick; D Hauser; P Pfäffli; A Sauter; H J Tobler
Journal:  Adv Biochem Psychopharmacol       Date:  1983

8.  Characterization of alpha-adrenergic receptor subtypes in rat brain: estimation of ability of adrenergic ligands to displace 3H-dihydroergocyrptine from the receptor subtypes.

Authors:  T Haga; K Haga
Journal:  Life Sci       Date:  1980-01-21       Impact factor: 5.037

9.  High-affinity binding of (3H) 5-hydroxytryptamine to brain synaptosomal membranes: comparison with (3H) lysergic acid diethylamide binding.

Authors:  G M Fillion; J C Rousselle; M P Fillion; D M Beaudoin; M R Goiny; J M Deniau; J J Jacob
Journal:  Mol Pharmacol       Date:  1978-01       Impact factor: 4.436

10.  Studies on possible mechanisms of action of electroconvulsive therapy; effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters.

Authors:  J F Deakin; F Owen; A J Cross; M J Dashwood
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  9 in total

1.  A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.

Authors:  G Acton; C Broom
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

2.  Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines.

Authors:  H R Burki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

3.  [3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors.

Authors:  A Closse; W Frick; R Markstein; R Maurer; R Nordmann
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

5.  Effects of D2-dopaminergic receptor stimulation on the lordotic response of female rats.

Authors:  M M Foreman; J L Hall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Effects of D2-dopaminergic receptor stimulation on male rat sexual behavior.

Authors:  M M Foreman; J L Hall
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  Antihistaminic activity of stobadine in the peripheral and central nervous system.

Authors:  L Lukovic; J Machová
Journal:  Agents Actions       Date:  1988-04

8.  Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.

Authors:  R Jackisch; S Moll; T J Feuerstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

9.  Contrasting effects of bromocriptine on learning of a partially baited radial arm maze task in the presence and absence of restraint stress.

Authors:  B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2007-04-28       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.